Physician profile
James Cicchiello
NPI 1730144296
$2,588.86
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,796 · 2020: $471 · 2021: $123 · 2022: $199.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $987.77 | 2019-2021 | |
| Glaxosmithkline, LLC. | $317.47 | 2019-2022 | |
| Amgen INC. | $265.34 | 2019-2022 | |
| Novo Nordisk INC | $237.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $189.44 | 2019-2020 | |
| Pfizer INC. | $161.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.49 | 2019-2020 | |
| Gilead Sciences, INC. | $122.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $97.36 | 2020 | |
| Lilly USA, LLC | $58.34 | 2019-2020 | |
| Astellas Pharma US INC | $16.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cicchiello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.